Alnylam Pharmaceuticals, Inc. (ALNY)

Acerca de Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Al 3 de noviembre de 2026, la acción de Alnylam Pharmaceuticals, Inc. (ALNY) subió a $160.34, un alza de 1.48% (+$2.34) frente al cierre anterior. En la sesión, las acciones han operado entre $156.72 y $161.58. Eso ubica a ALNY cerca del mínimo de su rango de 52 semanas, de $156.00 a $479.79. Alnylam Pharmaceuticals, Inc. opera en el sector de pharmaceutical preparations y tiene una capitalización de mercado de aproximadamente $21.16 mil millones, con cerca de 1.66 millones de acciones negociadas.

Últimas noticias de ALNY

• Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026Yahoo Finance· 3 nov, 8:30 a.m. ETAHAISA
• Oracle upgraded, Reddit downgraded: Wall Street's top analyst callsYahoo Finance· 2 nov, 9:55 a.m. ET
• Should You Buy The Dip In Alnylam Stock?trefis.com· 2 nov, 9:39 a.m. ET
• Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resiliencebiopharmadive.com· 2 nov, 9:00 a.m. ET
• Buy, Sell, or Hold? Today’s Top Upgrades and Downgrades: Amazon.com, Coinbase Global, CrowdStrike, FormFactor, GameStop, L3Harris Technologies, Oracle, Reddit, Rivian Automotive, and More247wallst.com· 2 nov, 8:13 a.m. ET
• FDA Decision Watch: Regeneron And Roche’s Autoimmune Drugs, Capricor’s DMD Therapy In Spotlightstocktwits.com· 2 nov, 5:36 a.m. ET
• 5 Best High Growth Stocks Outside Big TechYahoo Finance· 31 oct, 5:39 p.m. ET
• Alnylam (ALNY) Stock Drops As Q3 Earnings Clash With Sales ConcernsYahoo Finance· 31 oct, 12:21 a.m. ET

Fuente: Yahoo Finance RSS · Actualizado el 3 de noviembre de 2026

¿Quieres titulares, alertas e investigación con IA de ALNY en un solo lugar? Crea una cuenta gratis →

• $ALNY @Pika_Capital is this one worth a consideration?

  @RookyMoves· 3 nov, 11:29 a.m. ET

• $ALNY 3.8x 26' Revenue. Market, are you okay?

  @AsymmetricUpsideEnjoyer· 3 nov, 11:28 a.m. ET

• $ALNY shitty management. FDA is in November. Alny will receive a payout and sales % if approved

  @Olena· 3 nov, 11:02 a.m. ET

• $ALNY Barclays maintains Alnylam Pharmaceuticals at Overweight, set price target to $380 🫠🫠🫠

  @sampeper· 3 nov, 10:51 a.m. ET· Alcista

• $ALNY breaking news: Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026 https://www.businesswire.com/news/home/20261103351345/en/Alnylam-to-Present-Five-Year-HELIOS-B-D…

  @sampeper· 3 nov, 10:50 a.m. ET· Alcista

Fuente: Stocktwits. Las publicaciones de usuarios son opiniones, no hechos verificados. Ver lo que es tendencia →